Big pharma Merck, Bristol Myers, J&J prepare to lose revenue
The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium.
NYSE
Big…
Bristol-Myers CEO talks new acquisitions: 'Writing the next chapter'
Bristol-Myers Squibb CEO Chris Boerner detailed the pharmaceutical giant’s bundle of recent…
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new…
Bristol Myers Squibb to buy Karuna Therapeutics
Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna…
Investors may be passing up three biopharma areas, Oppenheimer says
As biopharma investors follow the latest buzz around advancements in clinical research, they may be…
Biotechs that could rally 35%+ include one targeting Schizophrenia
With new drug launches and product approvals on the horizon, some biotechnology stocks could finally…
AI stocks to play the ChatGPT driven artificial intelligence craze
Every few years there’s a surge of renewed buzz around artificial intelligence. With the…
Citi names top biotech stock picks for 2023
Biotech has been a “stock-pickers market” — and it may have just what it takes to…
Big pharma still favored, but good bets in biotech are out there
Investors looking for cover this year would have done well if they sought a safe haven in large-cap…
